Announced details
Moderate-to-severe plaque psoriasis and scalp psoriasis. A Phase IIb trial is also underway in systemic lupus erythematosus.
PASI 90 response rate at Week 24: 68.0% for ONWARD1 and 62.1% for ONWARD2. PASI 100 response rate: 41.0% for ONWARD1 and 39.5% for ONWARD2. In patients with scalp psoriasis, approximately 75% achieved an ss-PGA score of 0/1 at Week 24, approximately 50% achieved a DLQI score of 0/1 at Week 12, and the WP NRS improved by an average of more than 4 points from baseline at Week 16.
More than 1,700 patients were enrolled in the Phase III ONWARD clinical program (as stated at the time of trial enrollment).
A partner from which Kaken Pharmaceutical has obtained the rights to develop, manufacture, and market ESK-001 in the dermatology field in Japan.
A Nasdaq-listed biotechnology company headquartered in South San Francisco, California, USA. It develops oral therapies for immune-mediated diseases. Its chief executive officer is Martin Babler.
ONWARD1：NCT06586112、ONWARD2：NCT06588738
South San Francisco, California, USA (Alumis headquarters)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
2026 American Academy of Dermatology Annual Meeting (AAD 2026); announcement by Alumis (URL: https://investors.alumis.com/news-events/news-releases)
| Item | Details |
|---|---|
| Names of Products / Services Covered | ESK-001, envudeucitinib |
| Counterparty | Alumis Inc.（Nasdaq：ALMS） |
| Counterparty overview | A Nasdaq-listed biotechnology company headquartered in South San Francisco, California, USA. It develops oral therapies for immune-mediated diseases. Its chief executive officer is Martin Babler. |
| Relationship with the Company | A partner from which Kaken Pharmaceutical has obtained the rights to develop, manufacture, and market ESK-001 in the dermatology field in Japan. |
| Applicable area | Moderate-to-severe plaque psoriasis and scalp psoriasis. A Phase IIb trial is also underway in systemic lupus erythematosus. |
| Registration number and expiry date | ONWARD1：NCT06586112、ONWARD2：NCT06588738 |
| Location | South San Francisco, California, USA (Alumis headquarters) |
| Quantitative Effects | PASI 90 response rate at Week 24: 68.0% for ONWARD1 and 62.1% for ONWARD2. PASI 100 response rate: 41.0% for ONWARD1 and 39.5% for ONWARD2. In patients with scalp psoriasis, approximately 75% achieved an ss-PGA score of 0/1 at Week 24, approximately 50% achieved a DLQI score of 0/1 at Week 12, and the WP NRS improved by an average of more than 4 points from baseline at Week 16. |
| Usage history | More than 1,700 patients were enrolled in the Phase III ONWARD clinical program (as stated at the time of trial enrollment). |
| Source | 2026 American Academy of Dermatology Annual Meeting (AAD 2026); announcement by Alumis (URL: https://investors.alumis.com/news-events/news-releases) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because Alumis presented the Phase III trial results at the 2026 American Academy of Dermatology Annual Meeting. The trials evaluated the efficacy and safety of ESK-001.